This project aims to investigate the effects of voluntary endurance training as secondary prevention immediately following a heart attack. The potential key enzyme, AMP-activated protein kinase (AMPK), will be modulated genetically and pharmacologically to identify the underlying mechanisms. Further examination of the interaction of AMPK with the immune checkpoint regulator CD40L-CD40 signaling cascade will be performed. The potential effects of anti-inflammatory therapy in the context of a heart attack will be investigated by genetically and pharmacologically modifying the CD40-TRAF6 axis. In particular, the focus of the study is also the investigation of the sex-specific differences in the regulation of proteins, endurance training, and possible treatment options to improve the prognosis after a heart attack. This project could uncover previously unknown mechanisms and possibly lead to more precise recommendations for physical activity following a heart attack. Specific preventive measures or pharmacological therapeutic strategies could be developed based on the findings.